Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS® (methylphenidate HCl) formulation

Journal of Clinical Pharmacology

Volumn 40, Issue 4, 2000, Pages 379-388

  Modi, N B ^a   Lindemulder, B ^a   Gupta, S K ^a  

^a ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; OROS;

AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; HUMAN; OSMOTIC MINIPUMP;

EID: 0033634743     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009080     Document Type: Article

References (18)

1. Synthesis and pharmacology of hydroxylated metabolites of methylphenidate
2. Pharmacokinetics of methylphenidate in man, rat, and monkey
3. Pharmacokinetics and actions of methylphenidate
4. A time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity
5. Psychopharmacology of attention deficit disorder: Pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate
6. Clinical studies of methylphenidate serum levels in children and adults
7. Sustained release methylphenidate: Pharmacokinetic studies in ADHD males
8. The absorption of sustained-release methylphenidate formulations compared to an immediate release formulation
9. Comparison of sustained-release and standard methylphenidate in the treatment of minimal brain dysfunction
10. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline
11. Effects of sustained-release and standard preparations of methylphenidate on attention deficit disorder
12. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder
13. Using psychostimulants to treat behavioral disorders of children and adolescents
14. Methylphenidate in the clinical office practice of child psychiatry
15. Pharmacologic treatment of attention deficit hyperactivity disorder
16. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder
17. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children
18. Pharmacokinetics of methylphenidate in hyperkinetic children